Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi最新文献

{"title":"[Progress in hematopoietic stem cell transplantation for acute myeloid leukemia].","authors":"X L Zhu, X J Huang, Y Wang","doi":"10.3760/cma.j.cn121090-20240422-00157","DOIUrl":"10.3760/cma.j.cn121090-20240422-00157","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem/progenitor cells. Although new drugs have emerged in recent years, the status of hematopoietic stem cell transplantation (HSCT) in AML still remains irreplaceable. This article reviews the adjustment of indications for HSCT in AML, donor selection, and updates of conditioning regimens, new prevention strategies for post-transplant relapse, new targeted drugs, immunotherapy combined with HSCT to improve the prognosis of relapsed and refractory AML, and optimization of transplantation technology for elderly AML.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 2","pages":"179-185"},"PeriodicalIF":0.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143711470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Prognostic value of prolymphocyte percentage in chronic lymphocytic leukemia].","authors":"Z L Zhang, J H Zhou, L X Xing, Y Wang, T L Qiu, R Wang, H Wang, L Fan, H Y Zhu, Y Miao, J Y Li","doi":"10.3760/cma.j.cn121090-20241205-00537","DOIUrl":"10.3760/cma.j.cn121090-20241205-00537","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the impact of peripheral blood prolymphocyte percentage on the prognosis of patients with chronic lymphocytic leukemia (CLL) . <b>Methods:</b> This study included 300 patients diagnosed with CLL at the Department of Hematology of Jiangsu Provincial People's Hospital from October 2011 to December 2020. The association between prolymphocyte percentage and other parameters was analyzed, and the optimal cutoff prolymphocyte percentage was determined by X-tile analysis. Further survival analysis and prognostic model construction were used to validate the predictive value of prolymphocyte percentage. <b>Results:</b> Of the 300 eligible patients with CLL who were enrolled, 50 received Bruton tyrosine kinase inhibitors (BTKi) as first-line treatment. The group with higher prolymphocyte percentage comprised more patients in the advanced stages (<i>P</i>=0.010) and had higher β(2)-microglobulin (<i>P</i><0.001), unmutated immunoglobulin heavy-chain variable region gene (<i>P</i><0.001), and TP53 aberration (<i>P</i>=0.004). The optimal cutoff percentage of prolymphocytes was 1%. Patients with a prolymphocyte percentage >1% had significantly shorter treatment-free survival (TFS) (<i>P</i><0.001) and overall survival time (<i>P</i>=0.007) than patients with a prolymphocyte percentage ≤1%. On multivariate analysis, prolymphocyte percentage >1% tended to have an independent prognostic value for TFS [<i>HR</i>=1.405 (95% <i>CI</i> 0.971~2.032), <i>P</i>=0.071]. Compared with the nomogram of CLL international prognostic index (CLL-IPI) alone, the nomogram of CLL-IPI combined with prolymphocyte percentage showed better discrimination (area under the curve: 0.778 <i>vs</i>. 0.637; <i>P</i>=0.006). In addition, patients with a prolymphocyte percentage >1% were more likely to progress after BTKi treatment (<i>P</i>=0.038) . <b>Conclusion:</b> Peripheral blood prolymphocyte percentage was associated with various clinical and biological parameters and prognosis among patients with treatment-naive CLL.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 2","pages":"140-146"},"PeriodicalIF":0.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143711414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Advancements in artificial intelligence for the precise diagnosis and treatment of hematological malignancies].","authors":"H X Yang, J Xiong, W L Zhao","doi":"10.3760/cma.j.cn121090-20241022-00409","DOIUrl":"10.3760/cma.j.cn121090-20241022-00409","url":null,"abstract":"<p><p>Hematological malignancy is a highly heterogeneous disease with complex biological characteristics and diverse clinical manifestations. Therefore, precise diagnosis and treatment are crucial and urgently needed. To further improve the accuracy of diagnosis and prognostication and to promote personalized therapy, artificial intelligence (AI) has been increasingly used. This study reviewed literature published in the last 5 years and summarized the application, benefits, and drawbacks of AI in the diagnosis, treatment, and prognosis of hematologic malignancies. Although AI can effectively improve the accuracy of diagnosis and therapy, low-quality data, poor interpretability of the model, and limited clinical transformation have impeded its popularization and application. In the future, the clinical application of AI in hematologic malignancy can be accelerated by establishing standards for clinical data processing, integrating multimodal information for accurate diagnosis and prognostication, and conducting systematic clinical verification of model algorithms.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 2","pages":"186-192"},"PeriodicalIF":0.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143711375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Familial erythrocytosis type 2 due to VHL germline mutations: a case report and literature review].","authors":"N N Liu, L J Pan, Z J Xiao, Z F Xu","doi":"10.3760/cma.j.cn121090-20241011-00390","DOIUrl":"10.3760/cma.j.cn121090-20241011-00390","url":null,"abstract":"<p><p>To enhance the understanding of familial erythrocytosis type 2 (ECYT2) resulting from compound heterozygous mutations in the VHL gene. <b>Methods:</b> We conducted a retrospective analysis of the case data from a patient with ECYT2 to investigate its pathogenesis, clinical features, diagnosis and treatment options, as well as prognosis, while also reviewing the relevant literature. <b>Results:</b> A 31-year-old man was admitted to the hospital due to facial and hand flushing that had persisted for 29 years. Whole exome sequencing revealed compound heterozygous mutations in VHL p.P81L and p.N90T. Both of his parents were found to carry only one of these heterozygous mutations, yet they exhibited normal phenotypes. Based on the patient's hematological tests, a clear diagnosis of ECYT2 was established. Following treatment with erythrocytapheresis and daily administration of aspirin at a dosage of 100 mg, the patient experienced relief from dizziness and headaches associated with blood hyperviscosity, without any thrombotic or bleeding complications during this period. <b>Conclusions:</b> ECYT2 is a rare group of autosomal recessive genetic disorders. This case of ECYT2, resulting from compound heterozygous mutations in the VHL gene, represents the first report in China. Clinically, it is characterized by elevated red cell mass, normal or increased serum erythropoietin levels, and normal hemoglobin oxygen affinity levels. These factors contribute to thrombotic and bleeding complications that can lead to early mortality.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 1","pages":"75-80"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical features and prognosis of splenic marginal zone lymphoma with POD24].","authors":"L Wang, Q Shi, W L Zhao, L Wang","doi":"10.3760/cma.j.cn121090-20240729-00285","DOIUrl":"10.3760/cma.j.cn121090-20240729-00285","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the clinical characteristics, prognosis, and risk factors associated with disease progression within 24 months (POD24) after diagnosis in patients with splenic marginal zone lymphoma (SMZL) . <b>Methods:</b> Clinical data from 88 newly diagnosed SMZL patients treated at Ruijin Hospital, Shanghai Jiaotong University School of Medicine, between December 2009 and October 2022, were retrospectively analyzed. Patients were grouped based on the presence of POD24 for prognostic evaluation and comparison of clinical features. <b>Results:</b> There were 45 males (51.1% ) and 43 females (48.9% ), with a median age of 59 (24-82) years at the time of diagnosis. Ten (11.4% ) cases occurred POD24. The overall survival (OS) time and progression- free survival (PFS) time in the POD24 group were shorten than non-POD24 group [median OS time: 77 (11-159) months <i>vs</i> not reached, <i>P</i><0.001; 15 (4-24) months <i>vs</i> 121 (24-154) months, <i>P</i><0.001]. Univariate Cox analysis showed that Eastern Cooperative Oncology Group (ECOG) score ≥ 2 [<i>HR</i>=8.942 (95% <i>CI</i> 1.097-72.910), <i>P</i>=0.041], age-adjusted International Prognostic Index (aaIPI) score of high-risk [<i>HR</i>=5.070 (95% <i>CI</i> 1.256-20.461), <i>P</i>=0.023], POD24 [<i>HR</i>=14.049 (95% <i>CI</i> 3.339-59.107), <i>P</i><0.001], occurrence of tissue transformation [<i>HR</i>=7.819 (95% <i>CI</i> 1.952-31.316), <i>P</i>=0.004], and disease unremission status after initial treatment [<i>HR</i>=6.080 (95% <i>CI</i> 1.439-25.690), <i>P</i>=0.014] were the influencing factors for OS in SMZL patients. Multivariate analysis showed that POD24 [<i>HR</i>=5.859 (95% <i>CI</i> 1.249-27.475), <i>P</i>=0.025] and occurrence of tissue transformation [<i>HR</i>=5.520 (95% <i>CI</i> 1.050-29.009), <i>P</i>=0.044] were independent prognostic factors affecting OS. Univariate logistic analysis showed that ECOG ≥ 2 [<i>HR</i>=7.556 (95% <i>CI</i> 1.498-38.110), <i>P</i>=0.014], high risk of aaIPI score [<i>HR</i>=5.500 (95% <i>CI</i> 1.378- 21.945), <i>P</i>=0.016], occurrence of tissue transformation [<i>HR</i>=8.000 (95% <i>CI</i> 1.759-36.383), <i>P</i>=0.007], and disease unremission status after initial treatment [<i>HR</i>=9.136 (95% <i>CI</i> 2.216-37.675), <i>P</i>=0.002] were the influencing factors of POD24. Multifactorial analysis showed that disease unremission after initial treatment [<i>HR</i>=8.253 (95% <i>CI</i> 1.681- 40.518), <i>P</i>=0.009] was an independent risk factor affecting POD24. <b>Conclusions:</b> POD24 and tissue transformation are independent poor prognostic factors for OS in SMZL patients. Patients with POD24 are at a higher risk of developing tissue transformation. The failure to alleviate the disease after initial treatment is an independent risk factor affecting POD24 patients.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 1","pages":"81-87"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP].","authors":"H J He, Y Li, H Tian, X Y Xu, J Su, X X Ge, D P Wu, Z Q Yu, J Yin","doi":"10.3760/cma.j.cn121090-20241107-00437","DOIUrl":"10.3760/cma.j.cn121090-20241107-00437","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the efficacy and safety of obinutuzumab combined with glucocorticoid-based therapy in patients with relapsed immune thrombotic thrombocytopenic purpura (iTTP). <b>Methods:</b> This study analyzed the efficacy and adverse reactions of four patients with relapsed iTTP who were treated with a combination of obinutuzumab and glucocorticoids to assess the effectiveness and safety of the treatment. <b>Results:</b> All four patients had a history of multiple relapses and had previously undergone treatment with rituximab and bortezomib. Three patients exhibited additional autoantibodies. Following the combined therapy, all patients achieved clinical remission, with ADAMTS13 activity returning to normal levels and inhibitors testing negative. During a median follow-up period of 11 months (range: 3-17 months), all patients maintained sustained remission. No severe adverse events were reported during treatment or follow-up. <b>Conclusion:</b> The combination of obinutuzumab and glucocorticoid-based therapy is effective and safe for treating relapsed iTTP.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 1","pages":"70-74"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The value of sequential organ failure assessment and its dynamic changes in predicting mortality in hematology intensive care unit].","authors":"J J Wang, J Zhang, B Zhang, Y C Cao, Y L Guo, P R Yu, X Q Zhang, X J Zhang, Y J Song","doi":"10.3760/cma.j.cn121090-20241130-00510","DOIUrl":"10.3760/cma.j.cn121090-20241130-00510","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the value of Sequential Organ Failure (SOFA) score and its dynamics (ΔSOFA) in predicting mortality in hematology care unit (HCU) . <b>Methods:</b> A retrospective clinical study was conducted on 79 critically ill hematologic patients admitted to the Center for Critical Care Medicine, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, between May and June 2024. SOFA scores and ΔSOFA were calculated within 2 days before and after HCU admission. The predictive value of SOFA and ΔSOFA in mortality was assessed using receiver operating characteristic (ROC) curve analysis. <b>Results:</b> Among the 79 patients, the HCU mortality rate was 54.4%. The SOFA scores on days 1-3 (D1, D2, and D3) and ΔSOFA on day 1 (ΔD_1) of all patients, leukemia patients and hematopoietic stem cell transplantation (HSCT) patients were significantly higher in the death group compared with the non-death group (all <i>P</i><0.05). ROC curve analysis revealed that the D_1, D_2, D_3 scores, and ΔD_1 significantly predicted mortality (<i>P</i><0.001), with areas under the curve (AUCs) of 0.786, 0.866, 0.901, and 0.843, respectively. The sensitivity values were 74.36%, 57.89%, 62.85%, and 86.84%, while specificity values were 70%, 100%, 100%, and 67.65%, respectively. In the HSCT group, the D_-1, D_1, D_2, D_ 3, scores and ΔD_1 were predictive of HCU mortality, with AUCs of 0.833, 0.794, 0.871, 0.846, and 0.795, respectively. Sensitivity values for these scores were 100%, 85.71%, 71.43%, 57.14%, and 57.14%, while specificity values were 73.33%, 70.59%, 91.33%, 100%, and 100%, respectively. In the leukemia group, the D_1, D_2, D_3 scores, and ΔD_1 were predictive of HCU mortality, with AUCs of 0.760, 0.829, 0.846, and 0.756, respectively. Sensitivity values were 71.43%, 78.57%, 53.85%, and 71.43%, while specificity values were 76.19%, 78.95%, 100%, and 63.16%, respectively. For all patients, the D_3 score exhibited the highest specificity, while the ΔD_1 demonstrated the highest sensitivity. For patients in both the HSCT and leukemia groups, the sensitivity and specificity values of the D_1 and D_3 scores exceeded those of the ΔD_1. <b>Conclusion:</b> For patients with hematologic critical illness, including leukemia and those undergoing HSCT hospitalized in the HCU, D_1, D_2, D_ 3 scores and ΔD_1 are significantly associated with HCU mortality.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 1","pages":"31-38"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Current situation and prospect of minimal residual disease in pediatric T cell acute lymphoblastic leukemia].","authors":"F F Niu, C Gao","doi":"10.3760/cma.j.cn121090-20240701-00239","DOIUrl":"10.3760/cma.j.cn121090-20240701-00239","url":null,"abstract":"<p><p>Pediatric T-cell acute lymphoblastic leukemia (T-ALL) has been attracted much attention due to its high aggressiveness and complexity of treatment. Recently, with the development of technology and clinical research, the curative effect of T-ALL in children has been significantly improved. However, the presence of minimal residual disease (MRD) is still a key factor affecting the outcomes of children with T-ALL. With the continuous development of detection methods, the clinical applications of real-time quantitative PCR, multi-parameter flow cytometry, and high-throughput sequencing technology, MRD can be detected accurately to achieve personalized and precise treatment for each patient. The purpose of this article is to review the current detection methods of MRD in T-ALL, the clinical significance of MRD monitoring and evaluation in multi-agent combined chemotherapy and hematopoietic stem cell transplantation, and applying MRD to measure the responsiveness and effectiveness of new therapies in recent T-ALLs. Research directions and potential treatment strategies in the near future were also proposed.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 1","pages":"97-102"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical characteristics and prognostic evaluation of patients with hematological disease and sepsis in the Hematological intensive care unit].","authors":"H T Li, D X Lu, D D Li, D Y Zhang, J Y Fu, Q Zhang, S J Fan","doi":"10.3760/cma.j.cn121090-20241204-00532","DOIUrl":"10.3760/cma.j.cn121090-20241204-00532","url":null,"abstract":"<p><p><b>Objective:</b> To identify the clinical characteristics and prognosis of patients with hematological disease and neutropenic sepsis in the hematological intensive care unit (HCU). <b>Methods:</b> A retrospective analysis was conducted on patients with hematological disease and sepsis who admitted to HCU, the First Affiliated Hospital of Harbin Medical University from October 2017 to October 2024, to examine the primary therapeutic options, prognosis, cause of death, and infectious features of sepsis. <b>Results:</b> A total of 245 septic patients were included in the study, comprising 88 cases in the neutropenic sepsis group (neutropenic group) and 157 cases in the non-neutropenic sepsis group (non-neutropenic group). Acute leukemia was more prevalent in the neutropenic group [55.68% (49/88) ]. At the time of admission to the HCU, the neutropenic group exhibited unstable vital signs, lower blood cell counts, higher inflammatory markers, elevated Sequential Organ Failure Assessment (SOFA) scores, increased creatinine levels (120.00 µmol/L <i>vs</i> 77.10 µmol/L, <i>P</i><0.01), higher total bilirubin levels (24.70 µmol/L <i>vs</i> 17.90 µmol/L, <i>P</i><0.01), and significantly elevated B-type natriuretic peptide levels (567.90 ng/L <i>vs</i> 134.50 ng/L, <i>P</i><0.01) compared with the non-neutropenic group. Furthermore, septic shock was more common in the neutropenic group [53.40% (47/88) <i>vs</i> 36.94% (58/157), <i>P</i><0.05]. The mortality rate was also higher in the neutropenic group [46.59% (41/88) ] compared with the non-neutropenic group [32.48% (51/157) ] (<i>P</i><0.05), with septic shock accounting for the majority of deaths [70.73% (29/41) ]. Infections caused by gram-negative bacteria [55.68% (49/88) vs 36.30% (57/157), <i>P</i><0.01] and fungi [14.77% (13/88) <i>vs</i> 6.36% (10/157), <i>P</i><0.05] were more common in the neutropenic group. However, lung infections were significantly less frequent in the neutropenic group (<i>P</i><0.01). Kaplan-Meier survival analysis revealed a substantially worse 28-day overall survival rate for the neutropenic group compared with the non-neutropenic group (<i>P</i><0.05) . <b>Conclusion:</b> Patients with hematological diseases and neutropenic sepsis presented with more severe clinical conditions, a higher likelihood of organ failure and septic shock, and significantly increased mortality compared with patients with non-neutropenic sepsis.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 1","pages":"58-63"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese expert consensus on diagnosis, treatment and management of critically ill patients in hematology intensive care unit (2025)].","authors":"","doi":"10.3760/cma.j.cn121090-20241206-00542","DOIUrl":"10.3760/cma.j.cn121090-20241206-00542","url":null,"abstract":"<p><p>Recently, survival rates for patients with hematological malignancies (HMs) have improved, but severe complications have also risen accordingly, and can escalate quickly. Establishing a hematology intensive care unit (HCU) is crucial for early detection and centralized monitoring of critically ill hematological patients, as well as the enhancement of diagnosis, treatment and prognosis and minimizing medical disputes. Based on the guidelines of intensive care unit and hematology department, combined with clinical operation experience of domestic HCU, this consensus is participated by several leading hematology centers in China. It outlines the necessity, configuration, admission standards, management, treatment principles, and strategies of HCU. An expert agreement on managing critically ill HCU patients was achieved. It is suggested that the blood centers with eligible critieria should actively establish HCU, aiming to further lowering the mortality rate of critically ill hematology patients.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"46 1","pages":"9-17"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}